Onco Actu du 30 novembre 2016

	2. Etiologie
Pancreatic cancer and diabetes – a cellular case of chicken and egg [Cancer Research UK] While the majority of people with diabetes will never develop pancreatic cancer, the question of whether diabetes could be a cause or a consequence of pancreatic cancer is an important one.
	3.1 Tabac
Quitting smoking in your 60s can still boost life expectancy [New Scientist] These data show that age at smoking initiation and cessation, both key components of smoking duration, are important predictors of mortality in US adults aged 70 years and older.
The Creative Way Public Health Advocates Are Trying To Get Hipsters To Quit Smoking [FastCompany] How do you get hipsters to stop smoking? Well, you throw them a party. That's the philosophy behind Commune, a program organized by a marketing-science agency called Rescue that employs the same social branding strategies used by cigarette makers.
Philip Morris could stop making conventional cigarettes [BBC News] Philip Morris International (PMI), the Swiss-headquartered giant created when America's Altria spun off its non-US interests eight years ago, has spent $3bn (£2.4bn) on creating the substitute cigarette.
Smoking boosts heart attack risk 8-fold for younger adults [Reuters] For the new study, the researchers used data collected between 2009 and 2012 on people over age 18 in South Yorkshire. The population included 1,727 individuals who were treated for STEMIs, which are major heart attacks caused by a blockage in one of the heart's main arteries. About 49 percent of the STEMI patients were current smokers, about 27 percent were ex-smokers and about 24 percent were never smokers.
Philip Morris CEO looks towards phasing out cigarettes [Reuters] "I believe there will come a moment in time where I would say we have sufficient adoption of these alternative products ... to start envisaging, together with governments, a phase-out period for cigarettes," Andre Calantzopoulos said in an interview on BBC Radio 4.
	4. Dépistage, diagnostic et pronostic
Summer Project Turns Into Leukemia Testing Breakthrough [NY Times] The new test for chronic myeloid leukemia can be run with a few dime-size spots on a paper card that can be mailed to a center for diagnosis. Dr. Jerald Radich, a leukemia specialist at the Fred Hutchinson Cancer Research Center, said that since his lab developed the test cards have arrived by mail and in luggage from Africa and Asia, still useful after heat, cold and weeks in transit.
	4.9 Dép., diag. & prono. - Sein
As revenue falls, a pioneer of cancer gene testing slams rivals with overblown claims [STAT] Desperate to protect its business, Myriad embarked on an aggressive strategy to undermine its new competitors, STAT has found. In interviews, genetic counselors, physicians, and competitors said the company deployed its national sales force to stoke fears that other companies’ BRCA tests are so faulty they miss potentially deadly mutations.
This Paris Clinic Can Diagnose Breast Cancer In A Single Day [GE Reports] Gustave Roussy’s arsenal of advanced imaging machines includes GE’s latest digital mammography system, Senographe Pristina. GE just received FDA approval for the machine and Pristina is on display at RSNA for the first time in the U.S.
	5. Traitements
Researchers develop a new molecule that reduces cancer growth in mice [Stanford Medicine] When I asked cancer researcher Amato Giaccia, PhD, to explain his new discovery, he told me to think of it in terms of a baseball glove. Pretend, he said, that the baseball glove is a receptor and the molecule we are targeting is the baseball.
Milder chemotherapy drug could extend the lives of some leukaemia patients [Cancer Research UK] In the latest study, published in The New England Journal of Medicine (link is external), the researchers found that patients whose cells carried a faulty p53 gene responded very well to decitabine. All 21 patients within this group went into remission.
Weaponized antibodies use new tricks to fight cancer [Nature] Next generation of Trojan-horse drugs designed to minimize damage to healthy cells.
	5.12 Immunothérapies
Pfizer, partner German Merck see FDA accept PD-L1 candidate for speedy review This also comes a month after the EMA said it was to also review avelumab for Merkel cell carcinoma.
Step aside AstraZeneca, Pfizer/Merck KGaA jump ahead, getting a speedy review for their checkpoint rival avelumab [EndPoints] The drug is currently in 30 clinical programs as the two players look to wedge their way into a multibillion-dollar market for drugs that are gaining wide use in treating cancer.
German Merck, Pfizer get FDA priority review for cancer drug [Reuters] Avelumab belongs to a new generation of biotech drugs that stop some tumors from hiding from the immune system, similar to Merck & Co's Keytruda or Roche's Tecentriq.
	5.12.1 Immunothérapies - partenariats
AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro [EndPoints] The deal builds on MedImmune’s teamwork on first creating the bispecific, which inhibits both Ang2 and VEGF pathways. AbPro will now employ its synthetic biology platform to refine the therapy and take it into the clinic with a spinout company operating under its organization.
	5.3 Traitements - FDA, EMA, NICE...
Off-label drug marketing: Who will decide what’s “truthful” when the evidence can’t be trusted? [HealthNewsReview] “Free speech” in this case is a cover for targeting doctors and other health care providers with information of dubious value by the marketing machines of corporations.
	5.3.4 Traitements - AMM (FDA, EMA)
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial [Ariad] Full approval granted through completion of accelerated approval commitments for rare cancer patients who may have no other targeted treatment options.
	5.4 Traitements - Economie
Breast cancer drug could prevent the disease in high-risk women [Cancer Research UK] The drug, which costs £1.19 for 28 tablets, has been shown to be “effective for the primary prevention of breast cancer”, according to the new guidelines.
NICE recommends 4p a day breast cancer drug [NICE] Women with a family history of breast cancer should be offered anastrozole, not tamoxifen, says NICE in draft guidance.
Healthy women should take breast cancer pill, says NICE [BBC News] There are now three drugs to choose from - tamoxifen, raloxifene and, for the first time, anastrozole. Anastrozole is cheaper than the other two and, for some women, has fewer side-effects and is more effective.
	5.5 ASCO
ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology [ASCO] Fifteen Individual Criteria Aim at Guiding Pathway Development, Implementation, and Analytics to Improve Care.
	5.7 SABCS
Genomic Health Announces Presentation of Multiple Oncotype DX® Studies at the 2016 CTRC-AACR San Antonio Breast Cancer Symposium, Reinforcing Value of Genomics in Precision Medicine [Genomic Health] The study findings reinforce the Company's leadership in individualizing breast cancer treatment decisions and the value of the Oncotype DX test in various stages of the disease.
	6. Lutte contre les cancers
Make Funding for Cancer Research a Global Priority, Say European and U.S. Organizations [AACR] The European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR) are calling on policymakers and leaders throughout the world to provide robust and sustained funding for cancer research.
The Economist Events' War on Cancer 2016 [PR Newswire] The Economist Events' second annual War on Cancer 2016 will bring together over 150 global leaders in oncology to explore solutions to the mismatch in progress and delivery in cancer care across Europe. The forum will discuss innovative approaches to cancer prevention and treatment, solutions to overcome shortcomings in delivery and examples of best practices and opportunities for cross-sectoral collaboration.
	6.10.1 Politiques (USA)
Congress to remove controversial payment reporting exemption in 21st Century Cures Act [STAT] Amid intense criticism, lawmakers have removed a controversial provision in the 21st Century Cures Act that would have exempted companies from reporting payments made to doctors for receiving continuing medical education sessions, medical journals, or textbooks.
	6.6 Publications
How a researcher’s request to correct one paper turned into 19 retractions [Retraction Watch] Last year, a cancer researcher wrote to the Journal of Biological Chemistry, asking to correct one of his papers. The journal responded by requesting the raw data used to prepare his figures. Then, in a follow-up request, it asked for raw data behind the figures in 20 additional published articles.
	6.7 DMP, Big Data & applis
One Obstacle to Curing Cancer: Patient Data Isn’t Shared [Harvard Business Review] Doctors in academic centers are promoted for their research. Having exclusive use of their own data is crucial for gaining credit for research and obtaining grant money. Add to this the fact that many academic centers often cover the expenses of sequencing the genomes of their cancer patients themselves and you can understand their reluctance to share data.
	6.8 Communication
If I have cancer will I die? You asked Google – here’s the answer [The Guardian] Every day millions of internet users ask Google life’s most difficult questions, big and small. Our writers answer some of the commonest queries.